03107nam a2200361 4500 ESSALUD 20260804123817.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Torkildsen, Øivind Autor 53663 Rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis páginas: 32-43 Background: Anti-CD20 monoclonal antibodies are effective for relapsing multiple sclerosis. However, data from head-to-head trials are lacking. Methods: In this phase 3, multicenter, double-blind, noninferiority trial, we randomly assigned adults with newly diagnosed relapsing multiple sclerosis and recent disease activity in a 3:2 ratio to receive rituximab or ocrelizumab every 6 months for 24 months. The primary end point was the absence of new or enlarging lesions on T2-weighted magnetic resonance imaging (MRI) from month 6 to month 24. Noninferiority was defined as a lower limit of the 95% confidence interval for the risk difference (rituximab minus ocrelizumab) of greater than or equal to −10 percentage points. Secondary end points included efficacy and safety. Results: A total of 218 participants underwent randomization; 216 received treatment (132 assigned to the rituximab group and 84 assigned to the ocrelizumab group). Between months 6 and 24, the estimated probability of having no new or enlarging lesions detected on T2-weighted MRI was 92.2% with rituximab and 94.8% with ocrelizumab, corresponding to a risk difference of –2.6 percentage points (95% confidence interval, –9.4 to 4.3), which met the prespecified noninferiority criterion. Relapse rates, disability outcomes, and cognitive-performance profiles appeared to be similar in the two groups. Infections were more common in the rituximab group than in the ocrelizumab group (in 82% vs. 69% of participants), although the percentage of participants with serious adverse events was similar in the two groups (8% and 7%, respectively). Conclusions: In participants with newly diagnosed relapsing multiple sclerosis and recent disease activity, rituximab was noninferior to ocrelizumab in suppressing disease activity as detected by MRI from 6 to 24 months, with a similar incidence of serious adverse events. ALERGIA 7055 INMUNOLOGÍA GENERAL 53664 ENFERMEDAD AUTOINMUNE 53665 MEDICINA CLINICA GENERAL 53666 ENFERMEDAD INFLAMATORIA 53667 ESCLEROSIS MULTIPLE 14091 NEUROLOGÍA NEUROCIRUGÍA GENERAL 53668 OFTALMOLOGÍA 32364 Kjelgaard Brustad, Hilde 53669 Høgestøl, Einar August 53670 Alstadhaug, Karl Bjørnar 53671 Bhan, Alok 53672 Flemmen, Heidi Øyen 53673 Habbestad, Andrea 53674 22717 22634 Massachusetts NEJM Group NEJM001 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-07-31 sqb 22724 22724